Business Description
Zentalis Pharmaceuticals Inc
NAICS : 325411
SIC : 2833
ISIN : US98943L1070
Share Class Description:
ZNTL: Ordinary SharesTotal Employee Number:
106Description
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.2 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.23 | |||||
Debt-to-EBITDA | -0.22 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22.3 | |||||
3-Year EPS without NRI Growth Rate | 24.2 | |||||
3-Year FCF Growth Rate | 17.9 | |||||
3-Year Book Growth Rate | -24.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.55 | |||||
9-Day RSI | 42.97 | |||||
14-Day RSI | 43.55 | |||||
3-1 Month Momentum % | 17.88 | |||||
6-1 Month Momentum % | 70.16 | |||||
12-1 Month Momentum % | 163.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.82 | |||||
Quick Ratio | 4.82 | |||||
Cash Ratio | 4.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.2 | |||||
Shareholder Yield % | -0.52 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -65.21 | |||||
ROA % | -48.58 | |||||
ROIC % | -417.1 | |||||
3-Year ROIIC % | -158.52 | |||||
ROC (Joel Greenblatt) % | -504.65 | |||||
ROCE % | -61.31 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.9 | |||||
Price-to-Tangible-Book | 1.9 | |||||
EV-to-EBIT | -1.43 | |||||
EV-to-EBITDA | -1.43 | |||||
EV-to-Forward-Revenue | 10.74 | |||||
EV-to-FCF | -1.71 | |||||
| Price-to-Net-Current-Asset-Value | 2.48 | |||||
| Price-to-Net-Cash | 2.64 | |||||
Earnings Yield (Greenblatt) % | -69.93 | |||||
FCF Yield % | -35.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZNTL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zentalis Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.95 | ||
| Beta | 2.2015 | ||
| 3-Year Sharpe Ratio | -0.21 | ||
| 3-Year Sortino Ratio | -0.32 | ||
| Volatility % | 110.87 | ||
| 14-Day RSI | 43.55 | ||
| 14-Day ATR ($) | 0.263796 | ||
| 20-Day SMA ($) | 3.86225 | ||
| 12-1 Month Momentum % | 163.75 | ||
| 52-Week Range ($) | 1.212 - 6.95 | ||
| Shares Outstanding (Mil) | 94.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zentalis Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zentalis Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 61 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-14 14:35 | In 5 days | ||
| Wells Fargo 21st Annual Healthcare Conference | 2026-09-08 16:30 | 3.99 (-1.48%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 4.95 (+0.81%) | ||
| General meeting for 2026 | 2026-06-16 10:00 | 3.78 (-2.58%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 03:45 | 3.95 (-0.25%) | ||
| TD Cowen 6th Annual Oncology Innovation Summit | 2026-05-26 10:00 | 4.06 (-1.46%) | ||
| Guidance call for 2026 | 2026-05-20 16:30 | 3.54 (-1.39%) | ||
| H.C. Wainwright 4th Annual BioConnect Conference | 2026-05-19 14:30 | 3.63 (-9.25%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 4.14 (-6.12%) |
Show
Entries
Zentalis Pharmaceuticals Inc Frequently Asked Questions
What is Zentalis Pharmaceuticals Inc(ZNTL)'s stock price today?
The current price of ZNTL is $3.80. The 52 week high of ZNTL is $6.95 and 52 week low is $1.21.
When is next earnings date of Zentalis Pharmaceuticals Inc(ZNTL)?
The next earnings date of Zentalis Pharmaceuticals Inc(ZNTL) is 2026-11-10 Est..
Does Zentalis Pharmaceuticals Inc(ZNTL) pay dividends? If so, how much?
Zentalis Pharmaceuticals Inc(ZNTL) does not pay dividend.
Press Release
Articles on Zentalis Pharmaceuticals Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers